ADC Therapeutics (NYSE:ADCT - Get Free Report) will release its earnings data before the market opens on Thursday, November 7th. Analysts expect ADC Therapeutics to post earnings of ($0.35) per share for the quarter.
ADC Therapeutics (NYSE:ADCT - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. The company had revenue of $17.41 million during the quarter, compared to analysts' expectations of $19.06 million. During the same quarter in the previous year, the company earned ($0.58) earnings per share. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
ADC Therapeutics Stock Up 4.6 %
NYSE:ADCT traded up $0.13 on Friday, reaching $2.95. The company's stock had a trading volume of 186,565 shares, compared to its average volume of 635,616. ADC Therapeutics has a 12-month low of $0.36 and a 12-month high of $6.04. The stock has a 50 day moving average price of $3.02 and a 200 day moving average price of $3.39. The firm has a market cap of $285.24 million, a price-to-earnings ratio of -1.11 and a beta of 1.58.
Analyst Ratings Changes
ADCT has been the subject of several recent research reports. Royal Bank of Canada reissued an "outperform" rating and issued a $8.00 price objective on shares of ADC Therapeutics in a research note on Wednesday, August 7th. HC Wainwright reiterated a "buy" rating and set a $8.00 price target on shares of ADC Therapeutics in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $9.00.
Check Out Our Latest Stock Report on ADCT
About ADC Therapeutics
(
Get Free Report)
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Featured Stories
Before you consider ADC Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADC Therapeutics wasn't on the list.
While ADC Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
